JNJ vs ABBV — Key Metrics
| Metric | JNJ (JOHNSON & JOHNSON) | ABBV (ABBVIE INC) |
|---|---|---|
| Price | 272.7 | 286.01 |
| Market Cap | 656.47 Billion | 505.56 Billion |
| P/E (TTM) | 40.82 | 49.06 |
| P/B (Quarterly) | 7.611 | -109.235 |
| P/S (TTM) | 6.61 | 7.66 |
| Net Profit Margin (TTM) | 16.2 | 15.7 |
| Gross Margin (TTM) | 67.6 | 73.7 |
| ROE (TTM) | 19.6 | -201.0 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Outperform
Outperform
Recommendation Summary
Both stocks are projected to outperform the market over the next year. If you have to make a choice, Upfront Recommendation: ABBV.
Financial Metrics
| JNJ | Metrics | ABBV |
|---|---|---|
| $272.70 | Price | $286.01 |
| — | Market Capitalization | — |
| 40.82 | Price to Earnings Ratio | 49.06 |
| 6.61 | Price to Sales | 7.66 |
| 31.88 | Price to FCF Ratio | 26.79 |
| 9.78 | Price to Gross Profit | 10.39 |
| 40.82 | Price to R&D | 50.75 |
| 11.65 | Price to Current Assets | 13.49 |
JNJ vs ABBV at a glance
Johnson & Johnson (JNJ) and Abbvie INC (ABBV) are both Drug Manufacturers - General companies in the Healthcare sector. JNJ is the larger, at $656.5 billion in market value against $505.6 billion for ABBV, about 1.3 times the size.
On trailing-twelve-month figures, JNJ trades at 40.8 times trailing earnings and ABBV at 49.1; net profit margins are 16.2% and 15.7%.
The Upfront Investment model currently rates both Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.